Trial · NCT00585247
Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
NCT00585247, Not applicable, Completed, University of California, Irvine; results first posted 2018-04-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks. Trials, record NCT00585247. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00585247
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
- NCT number
- NCT00585247
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 27 participants, actual
- Lead sponsor
- University of California, Irvine
- Conditions
- Port Wine Stain
- Interventions
- Imiquimod, Placebo
- First posted
- 2008-01-03
- Last updated
- 2022-10-21
- Results first posted
- 2018-04-04
- Limitations and caveats
- Effects were evaluated after a single treatment and duration of effect is unknown
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in a* and E at 8 Weeks | 8 weeks baseline | Change in a\* and ΔE is a way to quantify PWS treatment outcome: a\* is the erythema of the vascular lesions and varies from +60 for green to -60 for red with a value of +9.28 for Normal Skin. Higher a\* values indicates a greater reduction in erythema hence better treatment outcome. ΔE detects all three dimensions of colorspace (L\*a\*b\*) and represents the difference in color between normal and PWS skin. Range of ΔE is 0 to 100. Higher values indicates improved treatment efficacy by greater skin color improvement. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in a* and E at 8 Weeks | 8 weeks baseline | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in a* and E at 8 Weeks | Imiquimod | a* | 1.27 | Standard Deviation 1.76 | units on a scale |
| Change From Baseline in a* and E at 8 Weeks | Placebo | a* | 0.43 | Standard Deviation 1.63 | units on a scale |
| Change From Baseline in a* and E at 8 Weeks | Imiquimod | ΔE | 4.08 | Standard Deviation 3.39 | units on a scale |
| Change From Baseline in a* and E at 8 Weeks | Placebo | ΔE | 2.59 | Standard Deviation 1.54 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Imiquimod | 14 | |
| Overall Study | STARTED | Placebo | 13 | |
| Overall Study | COMPLETED | Imiquimod | 14 | |
| Overall Study | COMPLETED | Placebo | 13 | |
| Overall Study | NOT COMPLETED | Imiquimod | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Imiquimod | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Imiquimod | 0 | 14 |
| Total, other adverse events | Placebo | 0 | 13 |
| Total, serious adverse events | Imiquimod | 0 | 14 |
| Total, serious adverse events | Placebo | 0 | 13 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22244840 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Imiquimod vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00585247
GET https://conductscience.org/api/trials/v1/NCT00585247/registered